新辅助腹腔内联合全身化疗对胃癌晚期腹膜转移的疗效探讨

Efficacy of Neoadjuvant Intraperitoneal Chemotherapy Combined with Systemic Chemotherapy in the Treatment of Advanced Peritoneal Metastasis of Gastric Cancer

目的:探讨新辅助腹腔内联合全身化疗(NIPS)对胃癌腹膜转移患者的临床有效性及安全性。方法:收集2017年1月-2018年1月经本科诊治经病理证实为胃腺癌腹膜转移的69例符合条件的晚期转移性胃癌患者,以2︰1的比例随机到IP组和SOX组。其中IP组46例,SOX组23例,比较两组患者相关临床指标。结果:与SOX组相比,IP组近期疗效显著(P=0.043)。两组患者随访12个月的中位生存时间(9.14个月vs 7.16个月)比较,差异有统计学意义(P=0.027)。两组毒副反应比较,差异无统计学意义(P>0.05)。结论:新辅助腹腔内联合全身化疗(NIPS)安全、可行,近期疗效显著。

Objective:To investigate the clinical efficacy and safety of neoadjuvant intraperitoneal chemotherapy combined with systemic chemotherapy(NIPS)in patients with peritoneal metastasis of gastric cancer.Method:From January 2017 to January 2018,69 patients with advanced metastatic gastric carcinoma confirmed by pathology were randomly assigned to IP group and SOX group.There were 46 cases in IP group and 23 cases in SOX group,the related clinical indicators of two groups were compared.Result:Compared with the SOX group,the short-term curative effect of the IP group was significant(P=0.043).The median survival time of 12 months was significantly different between the two groups(9.14 months vs 7.16 months)(P=0.027).There was no significant difference in toxicity and side effects between the two groups(P>0.05).Conclusion:Neoadjuvant intraperitoneal chemotherapy combined with systemic chemotherapy(NIPS)is safe,feasible and effective in the near future.